BMS’s Abecma Shakes Up Myeloma With Earlier-Line Approval From FDA

The US FDA approved Abecma for multiple myeloma after two prior lines of therapy, while the agency was also expected to imminently decide on earlier-line approval for J&J/Legend’s Carvykti.